Vertex Pharmaceuticals Q1 FY26: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jan 1 – Mar 31, 2026
- Reported
- May 5, 2026
Revenue$2.99B
+8% year over year
Gross profit$2.59B
87% margin
Operating profit$1.14B
38% margin
Net profit$1.03B
35% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 2.99 | 100% | +8% |
| Trikafta/Kaftrio | 2.36 | 79% | −7% |
| Alyftrek | 0.42 | 14% | +687% |
| Manufactured product other | 0.14 | 5% | −12% |
| Casgevy | 0.04 | 1% | +202% |
| Journavx | 0.03 | 1% | |
| Cost of revenue | −0.39 | 13% | |
| Gross profit | 2.59 | 87% margin | +0pp |
| SG&A | −0.49 | 17% | +2pp |
| Other | −0.96 | 32% | +0pp |
| Operating profit | 1.14 | 38% margin | +15pp |
| Other income, net | 0.12 | ||
| Tax | −0.22 | ||
| Net profit | 1.03 | 35% margin | +11pp |
175 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest